Related Experiment Videos
Subacute cutaneous lupus erythematosus associated with phenytoin
S Ross1, A D Ormerod, C Roberts
1Department of Dermatology, Aberdeen Royal Infirmary, Aberdeen UK.
Clinical and Experimental Dermatology
|October 10, 2002
Summary
Subacute cutaneous lupus erythematosus (SCLE) is a skin condition linked to systemic lupus erythematosus. This report details a rare case of SCLE triggered by the drug phenytoin, previously unassociated with this condition.
Area of Science:
- Dermatology
- Rheumatology
- Pharmacology
Background:
- Subacute cutaneous lupus erythematosus (SCLE) is a recognized subset of systemic lupus erythematosus (SLE).
- SCLE presents as a nonscarring, papulosquamous, or annular eruption, typically in sun-exposed areas.
- Drug-induced cases of SCLE have been documented, but specific associations are continually being identified.
Observation:
- This study reports a unique case of subacute cutaneous lupus erythematosus.
- The patient developed SCLE following exposure to the medication phenytoin.
- Phenytoin has not been previously implicated as a cause of SCLE.
Findings:
- Phenytoin was identified as the causative agent for subacute cutaneous lupus erythematosus in this patient.
- This represents a novel association between phenytoin and SCLE.
- The clinical presentation was consistent with established criteria for SCLE.
Implications:
- This finding expands the spectrum of known drug-induced SCLE.
- Clinicians should consider phenytoin as a potential trigger for SCLE in patients presenting with characteristic eruptions.
- Further investigation into the mechanisms of drug-induced SCLE may be warranted.